Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Oncocyte Corp (OCX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "ONCOCYTE REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS"
05/11/2023 8-K Quarterly results
Docs: "ONCOCYTE REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS"
11/10/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
08/10/2021 8-K Quarterly results
Docs: "Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
05/17/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "ONCOCYTE REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
07/30/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
03/25/2020 8-K Quarterly results
11/14/2019 8-K Quarterly results
05/14/2019 8-K Quarterly results
Docs: "ONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS"
04/01/2019 8-K Quarterly results
Docs: "ONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS"
11/13/2018 8-K Quarterly results
Docs: "ONCOCYTE REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROGRESS IN DETERMAVU™ DEVELOPMENT"
05/15/2018 8-K Quarterly results
Docs: "ONCOCYTE CORPORATION CONDENSED BALANCE SHEETS March 31, 2018 December 31, 2017 ASSETS CURRENT ASSETS Cash and cash equivalents $ 12,612 $ 7,600 Marketable equity securities 950 760 Prepaid expenses and other current assets 492 168 Total current assets 14,054 8,528 NONCURRENT ASSETS Intangible assets, net 686 746 Equipment and furniture, net 722 822 Deposits 120 120 TOTAL ASSETS $ 15,582 $ 10,216 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Amount due to BioTime and affiliates $ 2,105 $ 2,099 Accounts payable 307 175 Accrued expenses and other current liabilities 1,909 1,042 Loan payable, current 800 800 Capital lease liability, current 346 338 Total current liabilities 5,467 4,454 LONG-TERM LIABILITIES Loan payable, net of deferred financing costs, noncurrent 893 1,070 Capital ..."
04/02/2018 8-K Quarterly results
Docs: "OncoCyte Reports Fourth Quarter and Full Year 2017 Financial Results",
"OncoCyte Files Patents for 190 Newly Identified Novel Lung Cancer Biomarkers",
"OncoCyte Names Cavan Redmond Chairman of the Board of Directors"
04/28/2017 8-K Form 8-K - Current report
02/27/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
08/11/2016 8-K Form 8-K - Current report
05/19/2016 8-K Form 8-K - Current report
03/30/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy